1-4 of 4
Giangiacomo Torri
Close
Sort by
Journal Articles

Anti-Heparanase Therapy in Combination with Conventional Chemotherapy Potently Inhibits Multiple Myeloma Growth in Vivo

Joseph P. Ritchie, Annamaria Naggi, Giangiacomo Torri, Benito Casu, Claudio Pisano, Paolo Carminati, Israel Vlodavsky, Ralph D. Sanderson, Yang Yang
Journal: Blood
Blood (2008) 112 (11): 5165.
https://doi.org/10.1182/blood.V112.11.5165.5165
Published: 2008
Journal Articles

The Heparanase Inhibitor SST0001 Is a Potent Inhibitor of Myeloma Growth In Vivo

Yang Yang, Joseph P. Ritchie, Telisha Swain, Annamaria Naggi, Giangiacomo Torri, Benito Casu, Claudio Pisano, Paolo Carminati, Israel Vlodavsky, Ralph D. Sanderson
Journal: Blood
Blood (2008) 112 (11): 246.
https://doi.org/10.1182/blood.V112.11.246.246
Published: 2008
Journal Articles

A Heparin-Based Inhibitor of Heparanase Blocks Myeloma Growth In Vivo by Targeting the Tumor Microenvironment.

Yang Yang, MD, PhD, Telisha Swain, BA, Annamaria Naggi, PhD, Giangiacomo Torri, PhD, Benito Casu, PhD, Israel Vlodavsky, PhD, Ralph D. Sanderson, PhD
Journal: Blood
Blood (2007) 110 (11): 1502.
https://doi.org/10.1182/blood.V110.11.1502.1502
Published: 2007
Journal Articles

The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy

Yang Yang, Veronica MacLeod, Yuemeng Dai, Yekaterina Khotskaya-Sample, Zachary Shriver, Ganesh Venkataraman, Ram Sasisekharan, Annamaria Naggi, Giangiacomo Torri, Benito Casu, Israel Vlodavsky, Larry J. Suva, Joshua Epstein, Shmuel Yaccoby, John D. Shaughnessy, Jr, Bart Barlogie, Ralph D. Sanderson
Journal: Blood
Blood (2007) 110 (6): 2041–2048.
https://doi.org/10.1182/blood-2007-04-082495
Published: 2007